Literature DB >> 11045975

Nitric oxide-dependent pulmonary vasodilation in polycythemic rats.

B R Walker1, T C Resta, L D Nelin.   

Abstract

Polycythemia causes increased vascular production of nitric oxide (NO), most likely secondary to an effect of elevated vascular shear stress to enhance expression of endothelial nitric oxide synthase (eNOS). Because both polycythemia and increased eNOS expression are associated with chronic hypoxia-induced pulmonary hypertension, experiments were performed to test the hypothesis that increased hematocrit leads to upregulation of pulmonary eNOS and enhanced vascular production of NO independent of hypoxia. Rats were administered human recombinant erythropoietin (rEpo; 48 U/day) or vehicle for 2 wk. At the time of study, hematocrit was significantly greater in the rEpo-treated group than in the vehicle group (65.8 +/- 0.7% vs. 45.1 +/- 0.5%), although mean pulmonary artery pressure did not differ between treatments. Experiments on isolated, saline-perfused lungs demonstrated similar vasodilatory responses to the endothelium-derived NO-dependent agonist ionomycin in each group. Additional experiments showed that the vasoconstrictor response to the thromboxane mimetic U-46619 was diminished at lower doses in lungs from the rEpo group compared with the vehicle group. However, perfusate nitrite/nitrate concentration after 90 min of perfusion in isolated lungs was not different between groups. Additionally, no difference was detected between groups in lung eNOS levels by Western blot. We conclude that the predicted increase in shear stress associated with polycythemia does not result in altered pulmonary eNOS expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11045975     DOI: 10.1152/ajpheart.2000.279.5.H2382

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

1.  Enhanced brain release of erythropoietin, cytokines and NO during carotid clamping.

Authors:  Stephana Carelli; Giorgio Ghilardi; Paola Bianciardi; Elisa Latorre; Federico Rubino; Marina Bissi; Anna Maria Di Giulio; Michele Samaja; Alfredo Gorio
Journal:  Neurol Sci       Date:  2015-10-22       Impact factor: 3.307

2.  Erythropoietin and hypoxia increase erythropoietin receptor and nitric oxide levels in lung microvascular endothelial cells.

Authors:  Bojana B Beleslin-Čokić; Vladan P Cokić; Li Wang; Barbora Piknova; Ruifeng Teng; Alan N Schechter; Constance T Noguchi
Journal:  Cytokine       Date:  2011-02-15       Impact factor: 3.861

3.  Erythropoietin: when liability becomes asset in neurovascular repair.

Authors:  Maria B Grant; Michael E Boulton; Alexander V Ljubimov
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

4.  Chronic hypoxia augments depolarization-induced Ca2+ sensitization in pulmonary vascular smooth muscle through superoxide-dependent stimulation of RhoA.

Authors:  Brad R S Broughton; Nikki L Jernigan; Charles E Norton; Benjimen R Walker; Thomas C Resta
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-11-06       Impact factor: 5.464

5.  Combination of erythropoietin and sildenafil can effectively attenuate hypoxia-induced pulmonary hypertension in mice.

Authors:  Victor Samillan; Thomas Haider; Johannes Vogel; Caroline Leuenberger; Matthias Brock; Colin Schwarzwald; Max Gassmann; Louise Ostergaard
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

6.  Acute hemodynamic effects of erythropoietin do not mediate its cardioprotective properties.

Authors:  Ismayil Ahmet; Edward G Lakatta; Mark I Talan
Journal:  Biol Open       Date:  2012-08-22       Impact factor: 2.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.